AVTE Jun 2024 25.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:12PM EDT. Market open.
| Previous close | 0.0500 |
| Open | 0.0300 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 25.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0300 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 454 |
ZacksAerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.
Barrons.comAerovate Therapeutics Stock Dropped Over 90%. Here’s Why.
The company said its blood pressure drug failed in Phase 2 testing. The drug is its sole asset, according to Jefferies analysts.
Investor's Business DailyWhy 93% Of Aerovate Therapeutics' Value Just Went Up In Smoke
Aerovate Therapeutics said Monday its experimental blood pressure medicine failed in Phase 2 testing, and the biotech stock plummeted 93%.
© 2024 Yahoo. All rights reserved.